Presentation TCT 2017 New Trials: REGENT-VSEL Presenter: Timothy D. Henry, Marc S. Penn, Wojtek Wojakowski October 31, 2017
News Conference News TCT 2017 REVASC: CTO PCI Does Not Improve LV Function but Seems to Provide Symptom Relief Todd Neale October 31, 2017
Presentation TCT 2017 TCT 3: Outcomes of Left Main Revascularization in Patients With Acute Coronary Syndrome vs Stable Angina: Analysis From the EXCEL Trial Presenter: Rajesh M. Dave, A. Michael Lincoff, Marc Etienne Jolicoeur October 31, 2017
Presentation TCT 2017 Case Resolution: A Patient With Stable Angina Our Approach and Outcome Presenter: Sripal Bangalore, Manesh R. Patel, Adhir Shroff October 30, 2017
Presentation TCT 2017 Case Introduction: A Patient With Stable Angina How Should We Evaluate and Treat? Presenter: Sripal Bangalore, Manesh R. Patel, Adhir Shroff October 30, 2017
Presentation TCT 2017 Special Lecture: Treatment of Refractory Angina - Reducer-1 European Registry and US Approval Trial (With Discussion) Presenter: Philippe Genereux, Simon J. Walsh, Stefan Verheye October 30, 2017
News Conference News TCT 2017 Compared With Provisional Stenting, Double-Kissing Crush Technique Reduces Left Main Disease Events at 1 Year Yael L. Maxwell October 30, 2017
News Conference News TCT 2017 No Late Quality of Life Trade-offs With PCI in Left Main Disease: EXCEL-QOL Substudy Michael O'Riordan October 30, 2017
News Daily News Short-term Changes in Exercise Habits Can Alter Long-term Prognosis of Stable CAD Patients Caitlin E. Cox October 26, 2017
News Opinion Fellow Talk My Picks for Fellows Attending TCT 2017 Amit K. Gupta, MBBS, MD October 26, 2017
News Daily News Evolocumab ‘Abjectly Fails’ Another Financial Stress Test Michael O'Riordan October 19, 2017
News Daily News Secondary Prevention Lagging Behind in Women With Established Coronary Disease Todd Neale September 22, 2017
News Industry News New FOURIER Analysis Shows Repatha® (Evolocumab) Reduces Cardiovascular Events In Patients With Diabetes September 15, 2017
News Conference News ESC 2017 Ultra-Low LDL Levels? FOURIER Suggests Efficacy of Evolocumab Michael O'Riordan August 28, 2017
News Conference News ESC 2017 CANTOS: Anti-inflammatory Agent Canakinumab Modestly Reduces Major CVD Events Michael O'Riordan August 27, 2017
News Daily News Early Invasive Strategy Benefits Select High-Risk NSTE ACS Patients, Meta-analysis Suggests Michael O'Riordan August 14, 2017
News Daily News Money-Back Guarantee for Evolocumab Has Little Impact on Cost-Effectiveness Michael O'Riordan August 08, 2017